Granted Patent
B2
US 12,433,903 · App. 18/299,504 · Granted Oct 7, 2025
Cannabinoid derivatives and their use
Assignee:
DEMEETRA AGBIO, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, for example, in the treatment of a mental health disorder or chronic inflammatory disease.
Claims (19)
1. An oral pharmaceutical composition comprising
(i) a cannabinoid compound, wherein the cannabinoid compound consists of:
or a pharmaceutically acceptable salt thereof, and
(ii) a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , comprising
(i) the cannabinoid compound consisting of:
(ii) a pharmaceutically acceptable carrier.
3. A method of treating a chronic inflammatory disease in a subject in need thereof, the method comprising orally administering to the subject an oral pharmaceutical composition comprising:
(i) a cannabinoid compound, wherein the cannabinoid compound consists of:
and
(ii) a pharmaceutically acceptable carrier; and
wherein the chronic inflammatory disease is an inflammatory bowel disease.
4. The method of claim 3 , wherein the inflammatory bowel disease is Crohn's disease.
5. The method of claim 3 , wherein the inflammatory bowel disease is ulcerative colitis.
6. A method of treating a chronic inflammatory disease in a subject in need thereof, the method comprising orally administering to the subject a composition comprising a cannabinoid compound, wherein the cannabinoid compound consists of:
and
wherein the chronic inflammatory disease is an inflammatory bowel disease.
7. The method of claim 6 , wherein the inflammatory bowel disease is Crohn's disease.
8. The method of claim 6 , wherein the inflammatory bowel disease is ulcerative colitis.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 4, 2023
From: CRAWFORD, JOHN; CHENGELIS, CHRISTOPHER
To: DEMEETRA AGBIO, INC.
Reel/Frame 063536/0438 →
Continuity (3)
Continuation
PCTUS2022074534
· Aug 4, 2022
Provisional Application
63229442
· Aug 4, 2021
References Cited (140)
US 6630507B1
· Hampson et al.
· 2003
[cited by applicant]
US 20120172339A1
· Makriyannis et al.
· 2012
[cited by applicant]
US 20180296521A1
· Schrader
· 2018
[cited by examiner]
US 20190091198A1
· Bar-Lev Schleider
· 2019
[cited by applicant]
US 20210299081A1
· Yuan et al.
· 2021
[cited by applicant]
US 20210378950A1
· Mainella
· 2021
[cited by applicant]
US 20210393519A1
· Lucas et al.
· 2021
[cited by applicant]
US 20210393540A1
· Lucas et al.
· 2021
[cited by applicant]
US 20220064090A1
· Linciano et al.
· 2022
[cited by applicant]
US 20220127213A1
· Nahtigal
· 2022
[cited by applicant]
US 20220186231A1
· Schuetz et al.
· 2022
[cited by applicant]
US 20220220089A1
· Abdur-Rashid et al.
· 2022
[cited by applicant]
US 20220235023A1
· Adair et al.
· 2022
[cited by applicant]
US 20220265601A1
· Heldreth, Jr.
· 2022
[cited by applicant]
US 20220290200A1
· Milne et al.
· 2022
[cited by applicant]
US 20220387376A1
· Thomas et al.
· 2022
[cited by applicant]
US 20230000936A1
· Bryant et al.
· 2023
[cited by applicant]
US 20230032113A1
· Noel
· 2023
[cited by applicant]
US 20230047027A1
· Byrant et al.
· 2023
[cited by applicant]
US 20230059087A1
· Zhou et al.
· 2023
[cited by applicant]
US 20230089351A1
· Metcalf
· 2023
[cited by applicant]
CA 3044735A1
· 2019
[cited by applicant]
CA 3081858A1
· 2021
[cited by applicant]
WO WO2008107879A1
· 2008
[cited by applicant]
WO WO2013035114A1
· 2013
[cited by applicant]
WO WO2014198993A1
· 2014
[cited by applicant]
WO WO2016087649A2
· 2016
[cited by applicant]
WO WO2018091551A1
· 2018
[cited by applicant]
WO WO2019030762A2
· 2019
[cited by applicant]
WO WO2019036243A1
· 2019
[cited by applicant]
WO WO2019079677A1
· 2019
[cited by applicant]
WO WO2020024056A1
· 2020
[cited by applicant]
WO WO2020069214A2
· 2020
[cited by applicant]
WO WO2020077153A1
· 2020
[cited by applicant]
WO WO2020107119A1
· 2020
[cited by applicant]
WO WO2021071967A1
· 2021
[cited by applicant]
WO WO2021078412A1
· 2021
[cited by applicant]
WO WO2021105996A1
· 2021
[cited by applicant]
WO WO2021156839A1
· 2021
[cited by applicant]
WO WO2021158575A1
· 2021
[cited by applicant]
WO WO2021195517A2
· 2021
[cited by applicant]
WO WO2021195751A1
· 2021
[cited by applicant]
WO WO2021222288A1
· 2021
[cited by applicant]
WO WO2021243467A1
· 2021
[cited by applicant]
WO WO2021243468A1
· 2021
[cited by applicant]
WO WO2021245658A1
· 2021
[cited by applicant]
WO WO2022006498A1
· 2022
[cited by applicant]
WO WO2022036462A1
· 2022
[cited by applicant]
WO WO2022091080A1
· 2022
[cited by applicant]
WO WO2022099078A1
· 2022
[cited by applicant]
WO WO2022113071A2
· 2022
[cited by examiner]
WO WO2022133544A1
· 2022
[cited by applicant]
WO WO2022147470A1
· 2022
[cited by applicant]
WO WO2022182523A1
· 2022
[cited by applicant]
WO WO2022182527A1
· 2022
[cited by applicant]
WO WO2022183292A1
· 2022
[cited by applicant]
WO WO2022187973A1
· 2022
[cited by applicant]
WO WO2022213120A1
· 2022
[cited by applicant]
WO WO2022221367A1
· 2022
[cited by applicant]
WO WO2022254425A1
· 2022
[cited by applicant]
WO WO2022266765A1
· 2022
[cited by applicant]
WO WO2022266767A1
· 2022
[cited by applicant]
WO WO2023004414A1
· 2023
[cited by applicant]
WO WO2023010083A2
· 2023
[cited by applicant]
WO WO2023023621A1
· 2023
[cited by applicant]
“Good Laboratory Practice Bioscience,” O,O-dimethyl CBG (evidentiary reference) CAS 29106-16-9/RN (2017). (Year: 2017).
[cited by examiner]
Appendino, et al., “Antibacterial Cannabinoids from Cannabis sativa: A Structure-Activity Study”. J. Nat Prod. (Aug. 2008); 71(8): 1427-1430. Epub Aug. 6, 2008.
[cited by applicant]
Blaskovich, Mark A. et all. “The antimicrobial potential of cannabidiol”, Communications Biology (2021), 4(1), 18 pages.
[cited by applicant]
Borrelli, et al., “Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease”. Biochem Pharmacol (May 1, 2013); 85(9): 1306-1316. Epub Feb. 12, 2013.
[cited by applicant]
Borrelli F et al. “Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease”, J. Mol. Med. 2009, 87:1111-1121.
[cited by applicant]
CAPLUS RN 55824-15-2 Registry Entered STN: Nov. 16, 1984, 1 page.
[cited by applicant]
Chianese, Giuseppina et al. “A Nrf-2 Stimulatory Hydroxylated Cannabidiol Derivative from Hemp (Cannabis sativa)”, Journal of Natural Products (2022), 85(4), 1089-1097.
[cited by applicant]
Consroe et al. “Antiepileptic Potential of Cannabidiol Analogs”, J Clin Pharmacol. 1981; 21 :428S-436S.
[cited by applicant]
Costa et al. “Antiseizure Effects of Fully Characterized Non-Psychoactive
[cited by applicant]
Crombie, Leslie et al. “Cannabinoid bis-homologs: Miniaturized synthesis and GLC study”, Phytochemistry (Elsevier) (1975), 14(1), 213-220.
[cited by applicant]
Field “Cannabinoid compounds in South African
[cited by applicant]
Golliher, Alexandra E. et al. “Using (+)-carvone to access novel derivatives of (+)-ent-cannabidiol: The first asymmetric syntheses of (+)-ent-CBDP and (+)-ent- CBDV”, Tetrahedron Letters (2021), 67, 152891, 4 pages.
[cited by applicant]
Husni A. et al. “Evaluation of phytocannabinoids from high-potency Cannabis sativa using in vitro bioassays to determine structure-activity relationships for cannabinoid receptor 1 and cannabinoid receptor 2”, Medicinal…
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/074534 dated Jan. 11, 2023, 18 pages.
[cited by applicant]
Iseger et al. “A systematic review of the antipsychotic properties of cannabidiol in humans”, Schizophrenia Research 162 (2015) 153-161.
[cited by applicant]
Jamontt et al., “The effects of delta 9- tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and invitro motility disturbances in rat colitis,” British Journal of Pharmacology, 2010, vo…
[cited by applicant]
Jones et al., “Cannabidiol Displays Antiepileptiform and Antiseizure Properties in Vitro and in Vivo,” J Pharmacol Exp Ther., 332(2):559-577 (2010).
[cited by applicant]
Kasteel E. et al. “Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors”, Archives of Toxicology (2020) 94:2637-2661.
[cited by applicant]
Kogan N.M., et al. “Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity,” Molecules, Sep. 15, 2021, vol. 26(18), p. 1-16.
[cited by applicant]
Lahat A et al. “Impact of Cannabis Treatment on the Quality of Life, Weight and Clinical Disease Activity in Inflammatory Bowel Disease Patients: A Pilot Prospective Study”, Digestion 2012; 85:1-8.
[cited by applicant]
Lal S. et al. “Cannabis use amongst patients with inflammatory bowel disease”, Eur. J. Gastroenterol. Hepatol. 2011, 23(10):891-896.
[cited by applicant]
Linciano, Pasquale et al. “Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol”, Scientific Reports (2020), 10(1), 22019, 11 pages.
[cited by applicant]
Linciano, Pasquale et al. “The novel heptyl phorolic acid cannabinoids content in different
[cited by applicant]
Liu, Chang et al. “Identification of SARS-COV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity”, Molecules (202…
[cited by applicant]
Loscher et al., “The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models”, 1991 Epilepsy Res 8:171-189.
[cited by applicant]
Marihuana '84 [Eighty-Four], Proc. Oxford Symp. Cannabis (1985), Meeting Date 1984, 713-719. Editor(s): Harvey, D. J. Publisher: IRL, Oxford, UK, Dep. Psychol., Univ. Vermont, Burlington, VT, 05405, USA.
[cited by applicant]
Martin et al., “Structure-Anticonvulsant Activity Relationships of Cannabidiol Analogs,” National Institute on Drug Abuse, Research Monograph Series, 1987, 79:48-58.
[cited by applicant]
McGuire, P. et al., “Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial,” Am J Psychiatry (2018), 175:225-231.
[cited by applicant]
Naftali T et al. “Treatment of Crohn's Disease with Cannabis: An Observational Study”, Isr. Med. Assoc. J. 2011, 13:455-458.
[cited by applicant]
Papahatjis, Demetris P. et al. “C1′-Cycloalkyl Side Chain Pharmacophore in Tetrahydrocannabinols”, Journal of Medicinal Chemistry (2007), 50(17), 4048-4060.
[cited by applicant]
Robson et al. “Cannabinoids and Schizophrenia: Therapeutic Prospects”, Current Pharmaceutical Design, 2014; 20(13): 2194-2204.
[cited by applicant]
Salbini, Maria et al. “Oxidative Stress and Multi-Organel Damage Induced by Two Novel Phytocannabinoids, CBDB and CBDP, in Breast Cancer Cells”, Molecules (2021), 26(18), 5576, 19 pages.
[cited by applicant]
Sampson, Peter B. “Phytocannabinoid Pharmacology: Medicinal Properties of Cannabis sativa Constituents Aside from the Big Two”, Journal of Natural Products (2021), 84(1), 142-160.
[cited by applicant]
Schicho R et al. “Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice”, Pharmacology 2012, 89:149-155.
[cited by applicant]
Schwarzenberg, Adrian et al. “Characterizing degradation of cannabidiol in e-liquid formulation”, Scientific Reports (2022), 12(1), 20058.
[cited by applicant]
U.S. Appl. No. 63/229,442, inventors Crawford; John et al., filed Aug. 4, 2021.
[cited by applicant]
U.S. Appl. No. 63/032,771, filed Jun. 1, 2020.
[cited by applicant]
Behrendt, H.-J. et al., “Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay,” British Journal of Pharmacology, 141:737-745…
[cited by applicant]
CAS Registry Record for 2-(3,7-Dimethylocta-2,6-dien-1-YL)-3-methoxy-5-pentylphenol {CAS#29106-17-0), entered Nov. 16, 1984, 3 pages.
[cited by applicant]
CAS Registry Record for 2-[(2E)-3,7-dimethyl-2,6-octadien-1-yl]-1,3-dimethoxy-5-pentyl-benzene {CAS#29106-16-9), entered Nov. 16, 1984, 3 pages.
[cited by applicant]
CELEBREX ® (celecoxib) capsules, for oral use, Initial U.S. Approval: 1998 (Revised Apr. 2021); product label; 23 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/299,511 dated Sep. 19, 2023, 11 pages.
[cited by applicant]
Restriction Requirement for U.S. Appl. No. 18/299,511 dated Aug. 24, 2023, 10 pages.
[cited by applicant]
Ruhaak, et al., “Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa”. Biol Pharm Bull. (2011); 34(5): 774-778.
[cited by applicant]
Vanachayangkul et al. “Inhibition of Heme Peroxidases by Melamine”, Hindawi Publishing Corporation, Enzyme Research, vol. 2012, Article ID 416062, Jun. 5, 2012, 7 pages.
[cited by applicant]
Araki, S. et al. “An efficient regio- and stereospecific alkenylation of phenolic ethers”, Chemistry Letters (1982), (6), p. 797-800.
[cited by applicant]
Bailey et al. “Distinction of Synthetic Cannabidiol, Cannabichromene, and Cannabivarin by GLC Using On-col. Methylation”, Journal of Pharmaceutical Sciences, Oct. 1975, vol. 64, No. 10, p. 1719-1720.
[cited by applicant]
Caprioglio et al. “O-Methyl Phytocannabinoids: Semi-synthesis, Analysis in Cannabis Flowerheads, and Biological Activity*”, Planta Med, 2019, 6 pages.
[cited by applicant]
El-Feraly et al. “Anisaldehyde as a sprey reagent for cannabinoids and their methyl ethers”, Acta Pharmatica Jugoslavica (1977), 27(1) , p. 43-46.
[cited by applicant]
Filonova, G., et al. “Next steps for the optimization of exon therapy for Duchenne muscular dystrophy,” Expert Opinion on Biological Therapy 2023, 23:2, 133-143.
[cited by applicant]
Han et al. “Synthesis and Cytotoxic Effects of Deoxy-tomentellin”, Arch Pharm Res 2000, vol. 23, No. 2, p. 121-127.
[cited by applicant]
Hanus et al., “Phyto-cannabinoids: a unified critical inventory,” Review Article, Natural Product Reports; Royal Society of Chemistry, vol. 33, No. 12, Dec. 2016, pp. 1347,1448, 37 pages.
[cited by applicant]
Luteyn et al. “Cannabis XVIII* Isolation and synthesis of olivetol derivatives formed in the pyrolysis of cannabidiol”, Recueil. Journal of the Royal Netherlands Chemical Society, (1978), 97(7-8), p. 187-190.
[cited by applicant]
Radwan et al. “Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis. Molecules,” May 8, 2021;26(9):2774 (29 pages).
[cited by applicant]
Small et al. “A Numerical Taxonomic Analysis of Cannabis with Special Reference to Species Delimitation”, Systematic Botany , Spring, 1976, vol. 1, No. 1, p. 67-84.
[cited by applicant]
Srebnik et al. “Base-catalysed Double-bond Isomerizations of Cannabinoids: Structural and Stereochemical Aspects”, Journal of the Chemical Society, Perkin Transactions I: Organic and Bio-Organic Chemistry (1972-1999), 1…
[cited by applicant]
Turner et al. “Constituents of
[cited by applicant]